File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: A randomized double-blind study with weekly endoscopic assessment

TitleOmeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: A randomized double-blind study with weekly endoscopic assessment
Authors
Issue Date1989
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH
Citation
Journal Of Gastroenterology And Hepatology, 1989, v. 4 SUPPL. 2, p. 35-43 How to Cite?
AbstractTo investigate the efficacy of standard and low dosage of omeprazole in the healing of duodenal ulcer, 270 patients with endoscopically active duodenal ulcer were randomized to receive omeprazole, 10 mg or 20 mg every morning, or ranitidine, 150 mg twice daily, using the double-dummy technique. Forty-six potential prognostic factors for healing including clinical, acid-secretory, and endoscopic characteristics were prospectively obtained and healing was assessed by endoscopy at weekly intervals for up to 4 weeks. The cumulative healing rates in the 4 weeks wete 43%, 77%, 94% and 95% for omeprazole,10 mg (n=83); 49%, 86%, 93% and 96% for omeprazole, 20 mg (n=87); and 29%, 63%, 83% and 93% for ranitidine (n=84), respectively. Life-table analysis showed P<0.03 for omeprazole, 10 mg versus ranitidine and P<0.002 for omeprazole, 20 mg versus ranitidine. Life-table analysis also showed that in omeprazole groups, healing rates were lower in smokers than in non-smokers (P<0.001), in late- than in early-onset patients (symptoms starting after or before the age of 30 years, respectively, P<0.02), in those with less than 5 months than in those with more than 5 months of remission (P<0.05), and in those with increased maximal acid output than in those with normal output (P<0.05). Patients with healed ulcer were interviewed at 2-month intervals and endoscoped at 4-month intervals or whenever symptoms recurred. The cumulative ulcer relapse rates in 1 year were not significantly different between omeprazole and ranitidine groups. It is concluded that (i) omeprazole, 10 mg daily or 20 mg daily, heals duodenal ulcer significantly faster than ranitidine, 150 mg twice daily; (ii) despite potent acid inhibition, ulcer healing by omeprazole is adversely affected by cigarette smoking in the population studied; and (iii) ulcers healed with omeprazole or ranitidine relapsed at similar rates.
Persistent Identifierhttp://hdl.handle.net/10722/163523
ISSN
2015 Impact Factor: 3.322
2015 SCImago Journal Rankings: 1.190

 

DC FieldValueLanguage
dc.contributor.authorHui, WMen_US
dc.contributor.authorLam, SKen_US
dc.contributor.authorLau, WYen_US
dc.contributor.authorBranicki, FJen_US
dc.contributor.authorLok, ASFen_US
dc.contributor.authorTaing, MMen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorPang Poon, GPen_US
dc.date.accessioned2012-09-05T05:37:03Z-
dc.date.available2012-09-05T05:37:03Z-
dc.date.issued1989en_US
dc.identifier.citationJournal Of Gastroenterology And Hepatology, 1989, v. 4 SUPPL. 2, p. 35-43en_US
dc.identifier.issn0815-9319en_US
dc.identifier.urihttp://hdl.handle.net/10722/163523-
dc.description.abstractTo investigate the efficacy of standard and low dosage of omeprazole in the healing of duodenal ulcer, 270 patients with endoscopically active duodenal ulcer were randomized to receive omeprazole, 10 mg or 20 mg every morning, or ranitidine, 150 mg twice daily, using the double-dummy technique. Forty-six potential prognostic factors for healing including clinical, acid-secretory, and endoscopic characteristics were prospectively obtained and healing was assessed by endoscopy at weekly intervals for up to 4 weeks. The cumulative healing rates in the 4 weeks wete 43%, 77%, 94% and 95% for omeprazole,10 mg (n=83); 49%, 86%, 93% and 96% for omeprazole, 20 mg (n=87); and 29%, 63%, 83% and 93% for ranitidine (n=84), respectively. Life-table analysis showed P<0.03 for omeprazole, 10 mg versus ranitidine and P<0.002 for omeprazole, 20 mg versus ranitidine. Life-table analysis also showed that in omeprazole groups, healing rates were lower in smokers than in non-smokers (P<0.001), in late- than in early-onset patients (symptoms starting after or before the age of 30 years, respectively, P<0.02), in those with less than 5 months than in those with more than 5 months of remission (P<0.05), and in those with increased maximal acid output than in those with normal output (P<0.05). Patients with healed ulcer were interviewed at 2-month intervals and endoscoped at 4-month intervals or whenever symptoms recurred. The cumulative ulcer relapse rates in 1 year were not significantly different between omeprazole and ranitidine groups. It is concluded that (i) omeprazole, 10 mg daily or 20 mg daily, heals duodenal ulcer significantly faster than ranitidine, 150 mg twice daily; (ii) despite potent acid inhibition, ulcer healing by omeprazole is adversely affected by cigarette smoking in the population studied; and (iii) ulcers healed with omeprazole or ranitidine relapsed at similar rates.en_US
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGHen_US
dc.relation.ispartofJournal of Gastroenterology and Hepatologyen_US
dc.subject.meshAdulten_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDuodenal Ulcer - Drug Therapyen_US
dc.subject.meshDuodenoscopyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshOmeprazole - Therapeutic Useen_US
dc.subject.meshRanitidine - Therapeutic Useen_US
dc.subject.meshRecurrenceen_US
dc.titleOmeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: A randomized double-blind study with weekly endoscopic assessmenten_US
dc.typeConference_Paperen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2491360-
dc.identifier.scopuseid_2-s2.0-0024935708en_US
dc.identifier.volume4en_US
dc.identifier.issueSUPPL. 2en_US
dc.identifier.spage35en_US
dc.identifier.epage43en_US
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridHui, WM=7103196477en_US
dc.identifier.scopusauthoridLam, SK=7402279473en_US
dc.identifier.scopusauthoridLau, WY=7402933199en_US
dc.identifier.scopusauthoridBranicki, FJ=7003617514en_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridTaing, MM=6507998023en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridPang Poon, GP=6505643357en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats